文献速递泌尿生殖与妇科肿瘤放疗

中度大分割放疗联合或不联合雄激素抑制治疗中危前列腺腺癌的随机3期研究初步生活质量和毒性分析:PCG GU003

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003.
PubMed 文献 · Adv Radiat Oncol · 2022-12-09

PCG GU003随机3期研究纳入110例中危前列腺癌患者,随机接受中度大分割质子束治疗(70 Gy相对生物效应剂量/28次)联合或不联合6个月雄激素剥夺治疗(ADT)。急性及晚期≥2级泌尿生殖和胃肠道毒性两组相似;ADT组性和激素领域生活质量评分下降,治疗结束后6个月恢复至基线。

要点

  • ADT组性和激素领域生活质量平均评分下降,治疗结束后6个月恢复至基线。
  • 急性及晚期≥2级泌尿生殖和胃肠道毒性两组相似。
  • 问卷依从性在3、6、12、24个月分别为84%、82%、64%、42%。

核心结论

  • 中危前列腺癌患者接受6个月ADT后,性和激素领域生活质量在治疗结束后6个月恢复至基线。

研究设计与样本

  • PCG GU003为随机3期研究,2012年至2019年纳入中危前列腺癌患者,随机接受中度大分割质子束治疗(70 Gy相对生物效应剂量/28次)联合6个月ADT(n=55)或不联合ADT(n=55)。

主要发现

  • 中位随访32.4个月(范围5.5-84.6),基线生活质量问卷完成率92%(101/110)。
  • 基线美国泌尿协会症状指数中位数两组相当(ADT组6[11%] vs 无ADT组5[9%],P=0.359)。
  • 急性及晚期≥2级泌尿生殖和胃肠道毒性两组相似。
  • ADT组性和激素领域平均评分下降(性领域-16.1,P<0.001;激素领域-6.3,P<0.001)。
  • 激素领域时间特异性最大差异在3个月(-13.8,P<0.001)和6个月(-11.2,P<0.001);激素领域在治疗结束后6个月恢复至基线,性功能在ADT完成后6个月有向基线恢复的趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our objective was to report the quality of life (QoL) analysis and toxicity in patients with intermediate-risk prostate cancer treated with or without androgen deprivation therapy (ADT) in Proton Collaborative Group (PCG) GU003. METHODS AND MATERIALS: Between 2012 and 2019, patients with intermediate-risk prostate cancer were enrolled. Patients were randomized to receive moderately hypofractionated proton beam therapy (PBT) to 70 Gy relative biologic effectiveness in 28 fractions to the prostate with or without 6 months of ADT. Expanded Prostate Cancer Index Composite, Short-Form 12, and the American Urological Association Symptom Index instruments were given at baseline and 3, 6, 12, 18, and 24 months after PBT. Toxicities were assessed according to Common Terminology Criteria for Adverse Events (version 4). RESULTS: One hundred ten patients were randomized to PBT either with 6 months of ADT (n = 55) or without ADT (n = 55). The median follow-up was 32.4 months (range, 5.5-84.6). On average, 101 out of 110 (92%) patients filled out baseline QoL and patient-reported outcome surveys. The compliance was 84%, 82%, 64%, and 42% at 3, 6, 12, and 24 months, respectively. Baseline median American Urological Association Symptom Index was comparable between arms (6 [11%] ADT vs 5 [9%] no ADT, P = .359). Acute and late grade 2+ genitourinary and gastrointestinal toxicity were similar between arms. The ADT arm experienced a QoL decline of mean scores in the sexual (-16.1, P < .001) and hormonal (-6.3, P < .001) domains, with the largest time-specific hormonal differences at 3 (-13.8, P < .001) and 6 (-11.2, P < .001) months. The hormonal QoL domain returned to baseline 6 months after therapy. There was a trend to baseline in sexual function 6 months after completion of ADT. CONCLUSIONS: After 6 months of ADT, sexual and hormonal domains returned to baseline 6 months after completion of treatment for men with intermediate-risk prostate cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Laughlin BS, Thorpe CS, DeWees TA, et al. Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003. Adv Radiat Oncol. 2022. PMID: 36896215. doi:10.1016/j.adro.2022.101142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。